903 F. Supp. 2d 198
S.D.N.Y.2012Background
- Indirect Purchaser Plaintiffs allege antitrust/consumer protection harms from Defendants' DDAVP patent strategy and related FDA patent-citation conduct (Orange Book listing, citizen petition, Paragraph IVs).
- Defendants allegedly obtained the '398 patent through inequitable PTO misconduct and engaged in sham litigation and baseless petitions to delay generic entry.
- Federal court first-dismissed similar claims in the Direct Purchaser case; Second Circuit remanded and later settlement occurred; this case seeks injunctive relief, damages, and restitution nationwide for indirect purchasers.
- Plaintiffs pursue Section 16 injunctive relief, state-law claims across 28 states, and unjust enrichment claims; Defendants move to dismiss under Rule 12(b)(1)/(6).
- Court addresses standing, preemption, and merits of state-law claims, and denies Plaintiffs' Judicial Notice request.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Standing for injunctive relief under Section 16 | Plaintiffs seek ongoing relief to prevent future antitrust injury | No ongoing threat since patent unenforceable | Injunction claim dismissed; no plausible ongoing threat shown. |
| Article III standing for state-law claims | Named plaintiffs have standing in Florida, Pennsylvania, Illinois; class certification will address scope | Standing lacked for claims on out-of-state possibilities | Denied; standing considered non-barred at this stage; class issues defer to certification. |
| Preemption of state-law Walker Process-type claims | State-law claims not preempted; plead fraud before PTO and bad-faith marketplace conduct | Claims premised on PTO/FDA conduct are preempted | Not preempted; Walker Process-type and related claims plausibly pled and not duplicative of patent law. |
| TCPA and other state consumer-protection claims | State-law claims seek redress for indirect purchasers’ injuries via deceptive practices | TCPA preemption and class-action limitations apply; some claims barred | TCPA claims dismissed; certain state-CP claims (AZ, CO, ID, MI, NV, NM, NY, ND, SD, TN) addressed with mixed outcomes; Nebraska/NDTPA claims upheld where applicable. |
| Unjust enrichment claims against Illinois Brick states and autonomous claims | Indirect purchasers may pursue autonomous unjust enrichment where direct antitrust relief is unavailable | Illinois Brick bars indirect purchaser recovery; autonomous claims vary by state | Dismissal of unjust enrichment under many Illinois Brick-following states; autonomous claims denied without prejudice for Tennessee; some states allowed. |
Key Cases Cited
- Walker Process Equipment, Inc. v. Food Machinery & Chemical Corp., 382 U.S. 172 (U.S. 1966) (patent procured by knowingly fraudulent conduct can remove immunity from antitrust law)
- Dow Chemical Co. v. Exxon Corp., 139 F.3d 1470 (Fed. Cir. 1998) (preemption limits where claims address marketplace conduct vs. PTO misconduct)
- Nobelpharma AB v. Implant Innovations, Inc., 141 F.3d 1059 (Fed. Cir. 1998) (inequitable conduct broader than Walker Process; potential antitrust liability for fraud)
- Abbott Labs. v. Teva Pharm. USA, Inc., 432 F. Supp. 2d 408 (D. Del. 2006) (fraud-on-FDA claims may be preempted when framed as FDA labeling compliance issues)